Funding of over $1 billion will be provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the U.S. Department of Defense. Under the agreement, the vaccine, Ad26.COV2.S, will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses under an additional agreement.
The company is conducting research and development in collaboration with BARDA and oversight from the FDA. Recently published phase I/IIa clinical trial results were positive and the company is currently evaluating both one- and two-dose regimens.
Copyright © 2020 scienceboard.net